dc.contributorFaculdade de Medicina de Jundiaí (FMJ)
dc.contributorUniversidade de São Paulo (USP)
dc.contributorNew York University
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:23:52Z
dc.date.available2014-05-27T11:23:52Z
dc.date.created2014-05-27T11:23:52Z
dc.date.issued2009-03-01
dc.identifierAnais Brasileiros de Dermatologia, v. 84, n. 2, p. 111-122, 2009.
dc.identifier0365-0596
dc.identifier1806-4841
dc.identifierhttp://hdl.handle.net/11449/70945
dc.identifier10.1590/S0365-05962009000200003
dc.identifierS0365-05962009000200003
dc.identifier2-s2.0-67449127608
dc.identifier2-s2.0-67449127608.pdf
dc.description.abstractAutoimmune bullous dermatoses are diseases in which blisters and vesicles are the primary and fundamental types of skin lesion. Their classification is based on the location of the blister: intraepidermal and subepidermal. Patients produce autoantibodies against self-specific structures of the skin detectable by immunofluorescence techniques, immunoblotting and ELISA. Recent advances in molecular and cellular biology have brought to knowledge these self-antigens, against which patients are sensitized, and which are found in epidermis or in the dermo-epidermal junction. These are low incidence, but high morbidity diseases that may be fatal. The aim of this article is to review and describe the progress of four autoimmune vesiculobullous disorders: endemic pemphigus foliaceous (wild fire), pemphigus vulgaris, bullous pemphigoid and dermatitis herpetiformis. ©2009 by Anais Brasileiros de Dermatologia.
dc.languagepor
dc.relationAnais Brasileiros de Dermatologia
dc.relation0.884
dc.relation0,520
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectAllergy and immunology
dc.subjectBullous pemphigoid
dc.subjectDermatitis herpetiformis
dc.subjectPemphigus
dc.subjectSkin diseases vesiculobullous
dc.subjectantibiotic agent
dc.subjectantigen
dc.subjectantiparasitic agent
dc.subjectautoantibody
dc.subjectazathioprine
dc.subjectchloroquine
dc.subjectcyclophosphamide
dc.subjectcyclosporin
dc.subjectdapsone
dc.subjectimmunoglobulin
dc.subjectmethotrexate
dc.subjectmethylprednisolone
dc.subjectmycophenolic acid 2 morpholinoethyl ester
dc.subjectnicotinamide
dc.subjectprednisone
dc.subjectriboflavin
dc.subjectrituximab
dc.subjectsulfone
dc.subjecttetracycline
dc.subjectbacterial infection
dc.subjectblister
dc.subjectbullous pemphigoid
dc.subjectchill
dc.subjectclinical classification
dc.subjectclinical feature
dc.subjectdermatitis herpetiformis
dc.subjectdiet therapy
dc.subjectdrug dose reduction
dc.subjectendemic disease
dc.subjectenzyme linked immunosorbent assay
dc.subjectepidermis
dc.subjectfever
dc.subjectgluten free diet
dc.subjectheadache
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthypotension
dc.subjectimmunoblotting
dc.subjectimmunofluorescence
dc.subjectincidence
dc.subjectknowledge
dc.subjectmorbidity
dc.subjectnausea
dc.subjectpathogenesis
dc.subjectpemphigus foliaceus
dc.subjectpemphigus vulgaris
dc.subjectplasmapheresis
dc.subjectpruritus
dc.subjectreview
dc.subjectskin defect
dc.subjectskin sensitization
dc.subjectstrongyle infection
dc.subjecttreatment duration
dc.subjecttreatment response
dc.subjecturticaria
dc.subjectAutoantibodies
dc.subjectAutoantigens
dc.subjectAutoimmune Diseases
dc.subjectDermatitis Herpetiformis
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectFluorescent Antibody Technique
dc.subjectHumans
dc.subjectImmunoblotting
dc.subjectPemphigoid, Bullous
dc.subjectSkin Diseases, Vesiculobullous
dc.titleDermatoses bolhosas auto-imunes
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución